Work

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Year: 2019

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-019-00776-6

Authors: Geoffrey I. Shapiro, Patricia LoRusso, Eunice Kwak, Susan Pandya, Charles M. Rudin, Carla Kurkjian, James M. Cleary, Mary Jo Pilat, Suzanne Jones, Alex de Crespigny, Jill Fredrickson, Luna Musib, Yibing Yan, Matthew Wongchenko, Hsin-Ju Hsieh, Mary R. Gates, Iris T. Chan, Johanna Bendell

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Yale Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma, Wayne State University, Sarah Cannon, Tennessee Oncology, Genentech

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Genentech

OpenAlex ID: W2940793077

FWCI: 2.649

Cites: 34

Cited by: 90

Related to: 10